CLCS Cell Source Inc.

Cell Source, Inc. is a biotechnology company, which engages in the development of cell therapy treatments based on the management of immune tolerance. The firm's lead product, Veto-Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company was founded on June 6, 2012 and is headquartered in New York, NY.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$1.14    OTCQB
As of 01/27/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/01/2014
Outstanding shares:  34,360,546
Average volume:  3,550
Market cap:   $34,360,546
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -5.13
PS ratio:   0.00
Return on equity:   58.02%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy